ClinicalTrials.gg
Active, not recruitingNCT04175678Updated Mar 10, 2026

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

An interventional study of Diet and Exercise in Healthy Lifestyle, Obese and Men, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

This is a rigorous, controlled clinical trial designed to show that diet, exercise training, and their combination in overweight, inactive men will alter epigenetic programming to create a "healthy" sperm epigenome. Our central hypotheses are: i) overweight and inactive lifestyle results in epimutations in the sperm epigenome relative to the normal epigenetic programming in lean and active men and ii) diet and exercise modulation leads to reversal of these epimutations resulting in both a healthier "phenotype" and "epigenotype" which may persist after stopping the interventions. The study is divided into three parts:

  1. We will recruit 20 healthy, active men and 20 obese and inactive Hispanic men between 18 and 40 years to determine the differences in sperm epigenome (DNA methylation, histone modifications and non-coding RNAs) in a cross-sectional study in obese inactive vs. healthy active Hispanic men. Only Hispanic men will be studied because of the high prevalence of obesity and inactivity in Hispanic younger men and to reduce the genetic variability influencing the epigenome.
  2. 80 obese and inactive men will be randomized to 4 groups of 20 men: 1) No intervention (control); 2) Low fat, low caloric diet; 3) Supervised, periodized endurance and resistance training without modification of diet; and 4) Both exercise and diet modification to characterize the plasticity of the sperm epigenome in response to 12-week diet and/or exercise training interventions in obese and inactive Hispanic men. Sperm epimutations will be compared before and after intervention within each group and between groups.
  3. The sperm epigenome studies in 80 men randomized to no intervention or diet and/or exercise training will be repeated at 12 and 36 weeks after cessation of interventions to Identify the persistent effects of diet and exercise training on the sperm epigenome after stopping the interventions.
Read the detailed description

This is not a clinical trial of a drug or device. This study will recruit 20 normal weight, physically active men and 80 obese, physically inactive Hispanic men aged between 18 and 40 years. The normal weight, active men will be studied at baseline only, whereas the obese, inactive men will be randomized and studied at baseline, after 12 weeks of diet modulation or exercise training. During the intervention period the participant will come to the study site at weeks 2, 4, 8, and 12. These men will be reassessed at 24 and 48 weeks (12 and 24 weeks) after cessation of intervention.

All research participants will be screened by medical history, physical examination, safety laboratory tests and depending on the BMI be eligible for the non-obesity or obese group. They will be provided with an accelerometer and nutritional survey and will return on day -14. If they meet the eligibility criteria then the non-obese, active men will be come for tests on day 1 and not further visits are required. The obese, inactive men and if they meet the criteria of that group they will be randomized to 1). No intervention; 2). Low fat and low caloric diet, 3). Exercise training; and 4) both diet modulation and exercise training for 12 weeks. Then they will be followed at 24 week and 48 weeks after start of treatment

02

Conditions studied

  • Healthy Lifestyle
  • Obese
  • Men

Keywords

  • Hispanic Men
  • Healthy Men
  • Obese Men
  • Exercise
  • Diet
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 100 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is the lead sponsor of 67 studies on the registry; 1 is open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine within the reference range at the time of screening
  2. Must have Hispanic Father and Mother from Mexico or Central America
  3. Normal weight, active subjects:

    • 18.5 - 24.9 calculated as weight in Kg/ (height in cm)2
    • Participates in ≥150 min/week of moderate intensity physical activity as assessed by accelerometer
    • Consume \< 30% of calories as fat/day
    • Fasting lipid panel within reference range or not above the reference ranges

    Obese and physically inactive subjects:

    • BMI ≥ 30 calculated as weight in Kg/ (height in cm)2 in obese subjects
    • Have risk factors for developing type 2 diabetes (first degree relatives with Diabetes Mellitus type 2, BP≥130/80, HDL-cholesterol ≤ 35mg/dL or triglycerides ≥200mg/dL, fasting plasma glucose ≥100mg/dl to 125mg/dL or HgbA1c ≥ 5.7 to 6.4%, abnormal liver transaminases (not more than 3 times suggestive of hepatic steatosis)
    • Participates in ≤150 min/week of moderate intensity physical activity
    • Consume >30 % fat as calories/day
    • Stable weight for past six months prior to the first screening visit
    • Willing to commit to 12 weeks of three times a week personalized exercise training
    • Willing to commit to 12 weeks of weight loss diet (low fat and low calories)
  4. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an and HIPAA form
  5. Does not meet any of the exclusion criteria.

Exclusion criteria

Exclusion Criteria:

  1. Men who meet any of the following criteria are NOT eligible for enrollment in the trial:
  2. Men participating in another clinical trial within the last 30 days prior to the first screening visit
  3. Men not living in the catchment's area of the clinic or within a reasonable distance from the site
  4. abnormal findings at screening except for those stated above for the obese, inactive group
  5. Abnormal serum chemistry values, according to local laboratory normal values that indicate chronic liver or kidney dysfunction or that may be considered clinically significant (except for obesity related abnormal laboratory tests including blood glucose, A1c, liver transaminases, lipids for the obese, active group as stated above). Other abnormal lab values may also be exclusionary, at the discretion of the investigator
  6. Sperm concentration below 15 million/mL in more than one of three screening samples
  7. Diastolic (D) blood pressure (BP) > 30 and Systolic (S) BP > 130 mm Hg for the healthy, non-obese and active group; and diastolic (D) blood pressure (BP) > 150 and Systolic (S) BP > 100 mm Hg for the obese, inactive group on in the opinion of the investigator not suitable for exercise training (BP will be taken 3 times at 5 minute intervals and the mean of all measurements be considered)
  8. History of hypertension, including hypertension controlled with treatment in the healthy, active group
  9. Known history of reproductive dysfunction including vasectomy or infertility
  10. Known history of cardiac, renal, hepatic, cardiac or respiratory disease
  11. A serious systemic disease such as diabetes mellitus defined by the American Diabetes Association or morbid obesity (body weight greater than 120% of ideal body weight or limitation as above)
  12. Known or suspected alcoholism or drug abuse or chronic infections
  13. Serious digestive and/or absorptive problems, including inflammatory bowel disease and
  14. Chronic food intolerance or diarrhea that preclude adherence to the study diet.
  15. Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity.
  16. Psychiatric disorders (including eating disorders) or conditions that, in the opinion of the investigator, would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder).
  17. History of other except: adequately treated non-melanoma skin cancer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Normal/Active

    No intervention

    Other: Standard care

  • Placebo comparator
    Obese/Inactive

    Observational clinic visits

    Other: Standard care

  • Experimental
    Diet

    low fat/low caloric diet

    Other: Diet

  • Experimental
    Exercise Training

    ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity

    Other: Exercise

  • Experimental
    Diet and exercise training

    low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity

    Other: Diet · Other: Exercise

Interventions

  • OtherDiet

    Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.

    Also known as: low fat/low cal diet

  • OtherExercise

    Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.

  • OtherStandard care

    Observational

06

What researchers measure

Primary outcomes

  1. Changes in the sperm epigenome

    The Primary endpoint is to compare alterations in the sperm epigenome (DNA methylation, histone modifications, non-coding RNAs) in obese, physically inactive men before and following diet modulation and/or exercise training; this will be contrasted to a parallel no intervention group.

    Time frame: 5 years

Secondary outcomes

  1. Sperm Epigenetic Signals

    1\. Compare differential sperm epigenetic signals between healthy, active Hispanic men at baseline with obese inactive men at baseline, and then after 12 weeks of diet modulation and/or exercise training or no intervention.

    Time frame: 5 years

  2. Effects of Diet and Exercise Training on the Sperm Epigenome

    2\. Characterize the effects of diet and exercise training on the sperm epigenome after stopping the interventions by comparing epigenetic data generated at the end of intervention, week 12, to data at week 24 and 48 after cessation of intervention;

    Time frame: 5 years

  3. Effects of Diet or /and Exercise on Phenotypic Features

    3\. Measure effects of a 12-week diet or/and exercise intervention (or 12 weeks of no intervention) in obese, inactive men by comparing changes in clinical/phenotype outcomes from baseline to end of study in Weight, BMI, Waist/Hip ratio, Glucose, Insulin, HOMA-IR, HbA1c, Plasma cholesterol, LDL, HDL, Triglyceride, VO2peak, muscle torque, and nutrient intake.

    Time frame: 5 years

  4. Analyze persistent effects of diet and/or exercise

    4\. Analyze the persistent effects (12 and 24 weeks after cessation of intervention) of the three intervention (diet, exercise, diet + exercise) groups and the obese, inactive no intervention control group.

    Time frame: 5 years

  5. Correlate alterations in sperm epigenome with clinical and biochemical fitness biomarkers

    5\. Characterize and correlate the alternations in sperm epigenome with clinical and biochemical and "fitness" biomarkers from baseline to 12 weeks of diet and/or exercise training or no modulation in obese, inactive men.

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — We will present the data first in abstract form in the Center's Annual Scientific Meeting (Retreat), then at national and international meetings. The data will be analyzed and published according to NIH guideline for publication and accepted manuscripts will be deposited to Pub Med Central to ensure public access.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Sep 2025, 66 months.

Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 66 months is above that.

Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2019
First posted
Nov 25, 2019
StartActual
Feb 21, 2020
Primary completionActual
Sep 3, 2025
CompletionEst.
Jun 30, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04175678
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Responsible party
Christina C L Wang, M.D. (Principal Investigator, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center) — Principal investigator
First posted
Nov 25, 2019
Start date
Feb 21, 2020
Primary completion
Sep 3, 2025
Completion
Jun 30, 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Christina Wang, MD
principal investigator · The Lundquist Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion